Concepts (266)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Hidradenitis Suppurativa | 12 | 2021 | 309 | 4.15 | Why? |
| Pyoderma Gangrenosum | 8 | 2018 | 41 | 2.44 | Why? |
| Urticaria | 9 | 2020 | 472 | 2.13 | Why? |
| Pemphigoid, Bullous | 4 | 2019 | 89 | 1.89 | Why? |
| Exanthema | 6 | 2021 | 1097 | 1.79 | Why? |
| Sweet Syndrome | 5 | 2018 | 54 | 1.76 | Why? |
| Omalizumab | 6 | 2019 | 158 | 1.71 | Why? |
| Skin | 11 | 2020 | 2096 | 1.70 | Why? |
| Skin Diseases | 7 | 2021 | 2509 | 1.45 | Why? |
| Antibodies, Antineutrophil Cytoplasmic | 2 | 2018 | 140 | 1.34 | Why? |
| Chickenpox | 2 | 2020 | 194 | 1.29 | Why? |
| Immunoglobulin E | 3 | 2018 | 557 | 1.28 | Why? |
| Adalimumab | 3 | 2021 | 389 | 1.18 | Why? |
| Neutrophils | 6 | 2019 | 5476 | 1.14 | Why? |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 2 | 2018 | 235 | 1.11 | Why? |
| Anti-Allergic Agents | 5 | 2019 | 167 | 1.11 | Why? |
| Clobetasol | 2 | 2018 | 25 | 0.84 | Why? |
| Linear IgA Bullous Dermatosis | 1 | 2019 | 11 | 0.81 | Why? |
| Acrodermatitis | 1 | 2020 | 60 | 0.80 | Why? |
| Chilblains | 3 | 2021 | 1156 | 0.80 | Why? |
| Dermatitis | 2 | 2019 | 188 | 0.79 | Why? |
| Autoimmunity | 4 | 2019 | 841 | 0.79 | Why? |
| Pemphigoid Gestationis | 1 | 2018 | 1 | 0.79 | Why? |
| Cutaneous Fistula | 1 | 2018 | 14 | 0.79 | Why? |
| Arthritis, Infectious | 2 | 2018 | 111 | 0.77 | Why? |
| Abscess | 2 | 2018 | 234 | 0.76 | Why? |
| Granulomatosis with Polyangiitis | 2 | 2018 | 161 | 0.74 | Why? |
| Pityriasis Rubra Pilaris | 1 | 2018 | 26 | 0.73 | Why? |
| Panniculitis | 1 | 2018 | 13 | 0.73 | Why? |
| Leukemia, Myelomonocytic, Chronic | 1 | 2018 | 37 | 0.71 | Why? |
| Acne Vulgaris | 2 | 2018 | 198 | 0.68 | Why? |
| Carcinoma, Neuroendocrine | 1 | 2018 | 57 | 0.68 | Why? |
| Hereditary Autoinflammatory Diseases | 1 | 2018 | 72 | 0.68 | Why? |
| Adrenal Gland Neoplasms | 1 | 2018 | 70 | 0.67 | Why? |
| Joints | 1 | 2018 | 97 | 0.67 | Why? |
| Skin Diseases, Vesiculobullous | 1 | 2018 | 112 | 0.66 | Why? |
| Systemic Vasculitis | 1 | 2018 | 74 | 0.66 | Why? |
| Herpes Simplex | 1 | 2020 | 272 | 0.64 | Why? |
| Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2018 | 88 | 0.64 | Why? |
| Blood Vessels | 1 | 2017 | 228 | 0.60 | Why? |
| Dermatitis, Atopic | 2 | 2021 | 714 | 0.60 | Why? |
| Spondylitis, Ankylosing | 1 | 2018 | 231 | 0.59 | Why? |
| Pancreatic Diseases | 1 | 2018 | 191 | 0.58 | Why? |
| Herpes Zoster | 1 | 2020 | 331 | 0.56 | Why? |
| Inflammasomes | 2 | 2019 | 710 | 0.56 | Why? |
| Skin Diseases, Viral | 1 | 2021 | 436 | 0.55 | Why? |
| Carcinoma | 1 | 2018 | 256 | 0.55 | Why? |
| Fibrinolysis | 1 | 2019 | 521 | 0.54 | Why? |
| Vasculitis | 2 | 2018 | 691 | 0.54 | Why? |
| Interleukin-17 | 2 | 2021 | 602 | 0.52 | Why? |
| Interleukin-1 | 1 | 2017 | 438 | 0.52 | Why? |
| Autoimmune Diseases | 4 | 2019 | 1996 | 0.51 | Why? |
| Neurodegenerative Diseases | 1 | 2019 | 469 | 0.50 | Why? |
| Diagnosis, Differential | 9 | 2020 | 7220 | 0.48 | Why? |
| Tumor Necrosis Factor-alpha | 3 | 2021 | 2483 | 0.45 | Why? |
| Pancreatic Neoplasms | 1 | 2018 | 609 | 0.42 | Why? |
| Fibrin Fibrinogen Degradation Products | 4 | 2019 | 5993 | 0.40 | Why? |
| Mucocutaneous Lymph Node Syndrome | 1 | 2021 | 1645 | 0.38 | Why? |
| Cytokines | 4 | 2019 | 15010 | 0.38 | Why? |
| Autoantibodies | 5 | 2019 | 2094 | 0.37 | Why? |
| Neutrophil Infiltration | 2 | 2019 | 201 | 0.35 | Why? |
| Dengue | 1 | 2020 | 1565 | 0.34 | Why? |
| Pregnancy Complications | 1 | 2018 | 1388 | 0.33 | Why? |
| Disease Susceptibility | 2 | 2021 | 4002 | 0.32 | Why? |
| Non-Fibrillar Collagens | 2 | 2019 | 9 | 0.32 | Why? |
| Inflammation | 4 | 2021 | 13255 | 0.31 | Why? |
| Biological Therapy | 2 | 2021 | 456 | 0.31 | Why? |
| Lung Diseases, Interstitial | 1 | 2017 | 1476 | 0.30 | Why? |
| Psoriasis | 4 | 2021 | 1739 | 0.30 | Why? |
| Keratosis | 1 | 2005 | 16 | 0.30 | Why? |
| Pemphigus | 2 | 2018 | 163 | 0.30 | Why? |
| Ultrasonography | 2 | 2018 | 4409 | 0.30 | Why? |
| Keratoacanthoma | 1 | 2005 | 14 | 0.30 | Why? |
| Vitamin D Deficiency | 1 | 2019 | 1782 | 0.30 | Why? |
| Lichenoid Eruptions | 1 | 2005 | 22 | 0.29 | Why? |
| Autoantigens | 3 | 2019 | 388 | 0.28 | Why? |
| Humans | 65 | 2021 | 930598 | 0.27 | Why? |
| Arthritis, Rheumatoid | 1 | 2018 | 2043 | 0.27 | Why? |
| Chronic Disease | 9 | 2021 | 5139 | 0.25 | Why? |
| Immunity, Innate | 2 | 2019 | 6570 | 0.25 | Why? |
| Histiocytosis, Non-Langerhans-Cell | 1 | 2002 | 6 | 0.25 | Why? |
| Livedo Reticularis | 2 | 2020 | 90 | 0.25 | Why? |
| Dermatitis, Exfoliative | 2 | 2018 | 50 | 0.22 | Why? |
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 6653 | 0.21 | Why? |
| Biological Products | 3 | 2021 | 2331 | 0.21 | Why? |
| Dystonin | 1 | 2019 | 4 | 0.21 | Why? |
| Pinocytosis | 1 | 2019 | 8 | 0.21 | Why? |
| Purpura | 2 | 2020 | 310 | 0.20 | Why? |
| Severity of Illness Index | 8 | 2021 | 48226 | 0.19 | Why? |
| Antibodies, Antinuclear | 2 | 2018 | 234 | 0.19 | Why? |
| Schnitzler Syndrome | 1 | 2018 | 3 | 0.19 | Why? |
| Malabsorption Syndromes | 1 | 2018 | 19 | 0.19 | Why? |
| Cryopyrin-Associated Periodic Syndromes | 1 | 2018 | 20 | 0.19 | Why? |
| Thyroglobulin | 1 | 2018 | 39 | 0.19 | Why? |
| Age of Onset | 1 | 2021 | 557 | 0.19 | Why? |
| Collagen Type VII | 1 | 2017 | 7 | 0.18 | Why? |
| Epidermolysis Bullosa Acquisita | 1 | 2017 | 7 | 0.18 | Why? |
| Fluorescent Antibody Technique, Direct | 1 | 2018 | 69 | 0.18 | Why? |
| Toes | 1 | 2020 | 252 | 0.17 | Why? |
| Anti-Inflammatory Agents | 1 | 2017 | 6153 | 0.17 | Why? |
| Fever of Unknown Origin | 1 | 2018 | 93 | 0.17 | Why? |
| Fingers | 1 | 2020 | 221 | 0.17 | Why? |
| Fluorescent Antibody Technique, Indirect | 1 | 2018 | 393 | 0.17 | Why? |
| Lupus Erythematosus, Cutaneous | 1 | 2018 | 104 | 0.17 | Why? |
| Administration, Cutaneous | 1 | 2018 | 229 | 0.17 | Why? |
| Skin Ulcer | 1 | 2018 | 98 | 0.17 | Why? |
| Mucous Membrane | 1 | 2019 | 305 | 0.16 | Why? |
| Thrombosis | 1 | 2019 | 7504 | 0.16 | Why? |
| Biopsy, Needle | 1 | 2018 | 303 | 0.16 | Why? |
| Betacoronavirus | 8 | 2020 | 204454 | 0.16 | Why? |
| Cholangitis | 1 | 2017 | 81 | 0.16 | Why? |
| Biomarkers, Pharmacological | 1 | 2017 | 150 | 0.16 | Why? |
| Immune System Diseases | 1 | 2021 | 410 | 0.16 | Why? |
| Interleukin-15 | 1 | 2017 | 169 | 0.16 | Why? |
| Histamine Antagonists | 1 | 2017 | 203 | 0.16 | Why? |
| Lipase | 1 | 2018 | 153 | 0.16 | Why? |
| Italy | 11 | 2021 | 38444 | 0.15 | Why? |
| Thromboplastin | 1 | 2018 | 275 | 0.15 | Why? |
| Dermatology | 3 | 2020 | 1999 | 0.15 | Why? |
| Multiple Myeloma | 1 | 2005 | 1064 | 0.14 | Why? |
| Pneumonia, Viral | 8 | 2020 | 243684 | 0.14 | Why? |
| Arthritis | 1 | 2018 | 288 | 0.14 | Why? |
| Biopsy | 3 | 2018 | 2811 | 0.14 | Why? |
| Coronavirus Infections | 8 | 2020 | 253789 | 0.14 | Why? |
| Adult | 19 | 2021 | 244371 | 0.14 | Why? |
| Female | 24 | 2021 | 380317 | 0.13 | Why? |
| Male | 20 | 2021 | 367725 | 0.13 | Why? |
| Child | 5 | 2021 | 70012 | 0.13 | Why? |
| Blood Proteins | 1 | 2017 | 551 | 0.13 | Why? |
| Genetic Predisposition to Disease | 2 | 2019 | 4027 | 0.13 | Why? |
| Th2 Cells | 1 | 2017 | 680 | 0.13 | Why? |
| Interleukin 1 Receptor Antagonist Protein | 2 | 2021 | 1165 | 0.13 | Why? |
| Patient Acuity | 1 | 2020 | 1755 | 0.13 | Why? |
| Bronchoalveolar Lavage | 1 | 2017 | 603 | 0.13 | Why? |
| Complement Activation | 1 | 2019 | 949 | 0.12 | Why? |
| Treatment Outcome | 7 | 2020 | 51732 | 0.12 | Why? |
| Aged | 14 | 2021 | 215776 | 0.12 | Why? |
| Syndrome | 1 | 2017 | 1310 | 0.12 | Why? |
| Leukocytes | 1 | 2019 | 1046 | 0.12 | Why? |
| Child, Preschool | 3 | 2021 | 36283 | 0.11 | Why? |
| Abdominal Pain | 1 | 2017 | 858 | 0.11 | Why? |
| Interleukins | 1 | 2017 | 762 | 0.11 | Why? |
| Colostomy | 1 | 2010 | 33 | 0.11 | Why? |
| Th1 Cells | 1 | 2017 | 1228 | 0.11 | Why? |
| Physician's Role | 1 | 2020 | 853 | 0.11 | Why? |
| Zinc | 1 | 2018 | 817 | 0.11 | Why? |
| Adolescent | 7 | 2020 | 86841 | 0.11 | Why? |
| Middle Aged | 17 | 2021 | 270681 | 0.10 | Why? |
| Patient Preference | 1 | 2017 | 750 | 0.10 | Why? |
| Immunohistochemistry | 1 | 2018 | 2275 | 0.10 | Why? |
| Retrospective Studies | 8 | 2020 | 105322 | 0.10 | Why? |
| Psychometrics | 1 | 2017 | 1269 | 0.10 | Why? |
| Blood Coagulation | 2 | 2019 | 2768 | 0.09 | Why? |
| Risk Assessment | 4 | 2021 | 25439 | 0.09 | Why? |
| Young Adult | 8 | 2021 | 93724 | 0.09 | Why? |
| Molecular Targeted Therapy | 1 | 2017 | 1579 | 0.09 | Why? |
| Complement C3 | 1 | 2010 | 271 | 0.09 | Why? |
| Bariatric Surgery | 1 | 2018 | 1298 | 0.09 | Why? |
| Immunoglobulin A | 1 | 2019 | 3567 | 0.08 | Why? |
| Bacteria | 1 | 2018 | 1897 | 0.08 | Why? |
| Pharmaceutical Preparations | 1 | 2021 | 1897 | 0.08 | Why? |
| Inflammation Mediators | 1 | 2018 | 2654 | 0.08 | Why? |
| Pandemics | 12 | 2021 | 389249 | 0.08 | Why? |
| Practice Guidelines as Topic | 3 | 2020 | 15421 | 0.08 | Why? |
| Erythema | 1 | 2010 | 400 | 0.08 | Why? |
| Enzyme-Linked Immunosorbent Assay | 2 | 2018 | 7868 | 0.08 | Why? |
| Biomarkers | 2 | 2019 | 23361 | 0.07 | Why? |
| Bacterial Infections | 1 | 2018 | 2229 | 0.07 | Why? |
| Aged, 80 and over | 5 | 2021 | 88759 | 0.07 | Why? |
| Immunotherapy | 1 | 2017 | 2421 | 0.07 | Why? |
| Eosinophils | 1 | 2010 | 848 | 0.07 | Why? |
| Registries | 2 | 2021 | 12327 | 0.06 | Why? |
| Antirheumatic Agents | 1 | 2018 | 3023 | 0.06 | Why? |
| Prognosis | 3 | 2020 | 32490 | 0.06 | Why? |
| Signal Transduction | 1 | 2019 | 7207 | 0.06 | Why? |
| Cohort Studies | 3 | 2021 | 36005 | 0.06 | Why? |
| Animals | 3 | 2019 | 78931 | 0.06 | Why? |
| Antibodies, Monoclonal | 1 | 2020 | 8041 | 0.05 | Why? |
| Receptors, Interleukin | 1 | 2021 | 83 | 0.05 | Why? |
| Interleukin-6 | 1 | 2019 | 7522 | 0.05 | Why? |
| Foundations | 1 | 2021 | 88 | 0.05 | Why? |
| Disease Management | 1 | 2019 | 6841 | 0.05 | Why? |
| Immunoglobulin M | 1 | 2018 | 9091 | 0.05 | Why? |
| Immunoglobulin G | 2 | 2017 | 21571 | 0.05 | Why? |
| Contact Tracing | 1 | 2020 | 8448 | 0.05 | Why? |
| Quality of Life | 2 | 2018 | 9820 | 0.05 | Why? |
| Infant, Newborn | 1 | 2021 | 23105 | 0.05 | Why? |
| Methylprednisolone | 1 | 2010 | 2107 | 0.05 | Why? |
| Immunosuppressive Agents | 1 | 2018 | 6331 | 0.05 | Why? |
| Telangiectasis | 1 | 2018 | 8 | 0.05 | Why? |
| Antigens, Nuclear | 1 | 2018 | 32 | 0.05 | Why? |
| Follow-Up Studies | 1 | 2018 | 17020 | 0.05 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 9335 | 0.05 | Why? |
| Receptors, CCR3 | 1 | 2017 | 7 | 0.04 | Why? |
| RNA, Small Cytoplasmic | 1 | 2018 | 71 | 0.04 | Why? |
| Th1-Th2 Balance | 1 | 2017 | 19 | 0.04 | Why? |
| Incidence | 4 | 2021 | 25622 | 0.04 | Why? |
| Infant | 1 | 2021 | 30274 | 0.04 | Why? |
| Glomerulonephritis | 1 | 2021 | 226 | 0.04 | Why? |
| Uveitis | 1 | 2021 | 233 | 0.04 | Why? |
| Ribonucleoproteins | 1 | 2018 | 151 | 0.04 | Why? |
| Lymphocytes | 1 | 2010 | 3056 | 0.04 | Why? |
| CD40 Ligand | 1 | 2017 | 121 | 0.04 | Why? |
| Interleukin-5 | 1 | 2017 | 138 | 0.04 | Why? |
| Receptors, CXCR3 | 1 | 2017 | 159 | 0.04 | Why? |
| Expert Testimony | 1 | 2021 | 658 | 0.04 | Why? |
| CD56 Antigen | 1 | 2017 | 193 | 0.04 | Why? |
| Microscopy, Fluorescence | 1 | 2017 | 335 | 0.04 | Why? |
| Blister | 1 | 2017 | 119 | 0.04 | Why? |
| Interleukin-12 | 1 | 2017 | 156 | 0.04 | Why? |
| Genome | 1 | 2019 | 341 | 0.04 | Why? |
| Global Burden of Disease | 1 | 2020 | 531 | 0.04 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.04 | Why? |
| Pregnancy | 1 | 2018 | 23879 | 0.04 | Why? |
| Pruritus | 1 | 2018 | 215 | 0.04 | Why? |
| Interleukin-13 | 1 | 2017 | 204 | 0.04 | Why? |
| Bacteriological Techniques | 1 | 2018 | 239 | 0.04 | Why? |
| Receptors, CCR5 | 1 | 2017 | 186 | 0.04 | Why? |
| Interleukin-4 | 1 | 2017 | 367 | 0.04 | Why? |
| Histones | 1 | 2018 | 371 | 0.04 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.04 | Why? |
| Blotting, Western | 1 | 2017 | 863 | 0.04 | Why? |
| Angioedema | 1 | 2017 | 111 | 0.04 | Why? |
| Evidence-Based Medicine | 2 | 2018 | 3228 | 0.04 | Why? |
| Comorbidity | 1 | 2019 | 34796 | 0.03 | Why? |
| Time Factors | 1 | 2018 | 31397 | 0.03 | Why? |
| Europe | 2 | 2021 | 12702 | 0.03 | Why? |
| Delphi Technique | 1 | 2018 | 1257 | 0.03 | Why? |
| Metabolic Syndrome | 1 | 2021 | 810 | 0.03 | Why? |
| Consensus | 2 | 2018 | 6345 | 0.03 | Why? |
| Myalgia | 1 | 2018 | 1015 | 0.03 | Why? |
| DNA | 1 | 2018 | 778 | 0.03 | Why? |
| Intestines | 1 | 2018 | 817 | 0.03 | Why? |
| Disease Outbreaks | 1 | 2020 | 27595 | 0.03 | Why? |
| C-Reactive Protein | 2 | 2018 | 7972 | 0.03 | Why? |
| Area Under Curve | 1 | 2018 | 2564 | 0.03 | Why? |
| Congresses as Topic | 1 | 2020 | 1347 | 0.03 | Why? |
| Proteomics | 1 | 2021 | 2481 | 0.03 | Why? |
| Surveys and Questionnaires | 1 | 2017 | 43792 | 0.02 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.02 | Why? |
| Proteome | 1 | 2019 | 1812 | 0.02 | Why? |
| Obesity, Morbid | 1 | 2018 | 1340 | 0.02 | Why? |
| Asymptomatic Diseases | 1 | 2020 | 3444 | 0.02 | Why? |
| Lung Diseases | 1 | 2021 | 2361 | 0.02 | Why? |
| Interferon-gamma | 1 | 2017 | 2711 | 0.02 | Why? |
| International Cooperation | 1 | 2020 | 3436 | 0.02 | Why? |
| Perception | 1 | 2017 | 2827 | 0.02 | Why? |
| Transcriptome | 1 | 2019 | 3466 | 0.02 | Why? |
| ROC Curve | 1 | 2018 | 6024 | 0.02 | Why? |
| Acute Disease | 1 | 2018 | 6029 | 0.02 | Why? |
| Emergencies | 1 | 2020 | 4095 | 0.02 | Why? |
| Rheumatic Diseases | 1 | 2021 | 2675 | 0.02 | Why? |
| Germany | 1 | 2020 | 9196 | 0.02 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2021 | 5837 | 0.02 | Why? |
| Inflammatory Bowel Diseases | 1 | 2021 | 3209 | 0.02 | Why? |
| Fever | 1 | 2018 | 7795 | 0.01 | Why? |
| Sex Factors | 1 | 2018 | 11014 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2017 | 11304 | 0.01 | Why? |
| Diabetes Mellitus | 1 | 2021 | 8207 | 0.01 | Why? |
| Case-Control Studies | 1 | 2017 | 17671 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2017 | 7330 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2020 | 25144 | 0.01 | Why? |
| Prospective Studies | 1 | 2018 | 43301 | 0.01 | Why? |
| Communicable Disease Control | 1 | 2021 | 29620 | 0.01 | Why? |
| Risk Factors | 1 | 2020 | 71621 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2018 | 53120 | 0.01 | Why? |